纽约肾移植受者COVID-19早期临床特征描述
该研究描述了哥伦比亚大学肾移植项目15例因确诊COVID-19住院的肾移植受者,最常见的表现为发热(87%)和咳嗽(67%),初始胸片多示双肺浸润但33%无急性影像学异常。患者接受免疫抑制减量并加用羟氯喹和阿奇霉素治疗,27%需机械通气,随访结束时过半出院回家。
要点
- 肾移植受者COVID-19表现与普通人群相似,发热和咳嗽最常见。
- 初始胸片33%无急性影像学异常,双肺浸润为最常见表现。
- 免疫抑制减量联合羟氯喹和阿奇霉素治疗与良好结局相关。
核心结论
- 肾移植受者COVID-19的临床表现与普通人群相似。
- 当前治疗方案(免疫抑制减量加羟氯喹和阿奇霉素)似乎与良好结局相关,但需更大队列更长随访验证。
研究设计与样本
- 回顾性描述性研究,纳入哥伦比亚大学肾移植项目中15例因确诊COVID-19住院的肾移植受者。
主要发现
- 患者最常见表现为发热(87%)和/或咳嗽(67%)。
- 初始胸片最常见双肺浸润,但33%无急性影像学发现。
- 27%的患者需要机械通气,随访结束时过半患者出院回家。
临床怎么用
- 肾移植受者感染COVID-19可表现为与普通人群相似的症状,发热和咳嗽常见。
- 管理上可考虑免疫抑制减量并加用羟氯喹和阿奇霉素,但需更多证据支持。
局限性
- 样本量小(15例),随访时间短,需更长随访和更大队列验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The novel SARS-CoV-2 virus has caused a global pandemic of coronavirus disease 2019 (COVID-19). Although immunosuppressed individuals are thought to be at an increased risk of severe disease, little is known about their clinical presentation, disease course, or outcomes. METHODS: We report 15 kidney transplant recipients from the Columbia University kidney transplant program who required hospitalization for confirmed COVID-19, and describe their management, clinical course, and outcomes. RESULTS: Patients presented most often with a fever (87%) and/or cough (67%). Initial chest x-ray most commonly showed bilateral infiltrates, but 33% had no acute radiographic findings. Patients were managed with immunosuppression reduction and the addition of hydroxychloroquine and azithromycin. Although 27% of our patients needed mechanical ventilation, over half were discharged home by the end of follow-up. CONCLUSIONS: Kidney transplant recipients with COVID-19 have presentations that are similar to that of the general population. Our current treatment protocol appears to be associated with favorable outcomes, but longer follow-up of a larger cohort of patients is needed.
引用
- Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York. J Am Soc Nephrol. 2020. PMID: 32317402. doi:10.1681/ASN.2020030375
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。